Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by davewhoon Jan 06, 2021 9:52am
199 Views
Post# 32231917

More consolidation in US health care

More consolidation in US health care• UnitedHealth to buy Change Healthcare for $7.84 billion to build up technology services UnitedHealth Group has agreed to buy Change Healthcare for $7.84 billion in cash, the companies said, to beef up its portfolio of healthcare technology services.

• UnitedHealth Group Inc and Change Healthcare Inc: UnitedHealth Group has agreed to buy Change Healthcare for $7.84 billion in cash, the companies said, to beef up its portfolio of healthcare technology services. The health insurer will pay $25.75 per Change Healthcare share in cash, a premium of 41.2% to Tuesday's closing price. The acquisition is expected to add to UnitedHealth's adjusted earnings per share by about 50 cents in 2022. Change Healthcare's platform, which manages revenue, payment cycles and clinical information, and Optum's data analytics solutions will help simplify clinical, administrative and payment processes, the companies said.
<< Previous
Bullboard Posts
Next >>